Eupraxia Pharmaceuticals (EPRX) Cash & Equivalents (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Cash & Equivalents of $58.5 million for Q1 2026, up 113.08% year-over-year from $27.5 million in Q1 2025, and down 27.39% quarter-over-quarter from $80.6 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Cash & Equivalents (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Cash & Equivalents for 5 consecutive years, with $58.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 113.08% year-over-year to $58.5 million; the TTM figure through Mar 2026 stood at $58.5 million (up 113.08% YoY), while the FY2025 annual figure was $80.6 million, up 143.38% from the prior year.
- Cash & Equivalents declined to $58.5 million in Q1 2026 per EPRX's latest filing, from $80.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $89.0 million in Q3 2025 and bottomed at $7.4 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $36.6 million across 5 years, with a median of $27.5 million in 2025.
- On a YoY basis, Cash & Equivalents climbed as much as 927.03% in 2025 and fell as far as 23.54% in 2025.
- Eupraxia Pharmaceuticals' Cash & Equivalents stood at $7.4 million in 2022, then surged by 160.23% to $19.3 million in 2023, then jumped by 71.14% to $33.1 million in 2024, then jumped by 143.38% to $80.6 million in 2025, then dropped by 27.39% to $58.5 million in 2026.
- Business Quant data shows EPRX's Cash & Equivalents at $58.5 million in Q1 2026, $80.6 million in Q4 2025, and $89.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 58.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.50 Mn |
| Dec 31, 2025 | 80.56 Mn |
| Sep 30, 2025 | 88.96 Mn |
| Jun 30, 2025 | 19.77 Mn |
| Mar 31, 2025 | 27.45 Mn |
| Dec 31, 2024 | 33.10 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 23.32 Mn |
| Mar 31, 2024 | 35.91 Mn |
| Dec 31, 2023 | 19.34 Mn |
| Dec 31, 2022 | 7.43 Mn |